In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Top Five Pharma Stories Of 2023

Executive Summary

The biopharma new year begins as the J.P. Morgan Healthcare Conference ends so here in no particular order, we take a look at five of the biggest stories of 2023, once again a year of highs and lows for the industry.

You may also be interested in...

Medicare Inflation Penalty Hits 64 Products In First Year

CMS’ latest update to the list of products subject to inflation rebates in the Part B brings the total number of different products that will owe rebates in the first year of the new penalty to 64. The headlines about big savings do not match the reality of very modest liabilities for the affected manufacturers.

Sanofi/AstraZeneca Resolving Beyfortus Shortage By Reallocating Southern Hemisphere Supply

With the White House putting a spotlight on US shortages of their new RSV monoclonal antibody, Sanofi and AstraZeneca can take some solace that the negative headlines stem from unexpectedly high demand and easier reimbursement for the immunization than the companies’ predicted.

Sickle Cell Drug Development Gains Momentum Across Disease Spectrum

The recent ASH meeting began with US FDA approvals of the first genetic medicines for sickle cell disease, but doctors and biopharma companies still see a need for new oral therapies and other options. 

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts